151751-Najiba-Chargi

61 Diagnostics: measuring skeletal muscle mass of the musculus masseter Table 1. (Continued) Characteristics All patients (n = 113) N (%) or Mean (±SD) Normal MSMI (n = 84) N (%) or Mean (±SD) Low MSMI (n = 29) N (%) or Mean (±SD) p-value Former 30 (35.4) 33 (39.3) 7 (24.1) Adult Comorbidity Evaluation-27 1.0 None 18 (15.9) 13 (15.5) 5 (17.2) Mild 38 (33.6) 29 (34.5) 9 (31.0) Moderate 34 (30.1) 25 (29.8) 9 (31.0) Severe 23 (20.4) 17 (20.2) 6 (20.7) Charlson Comorbidity Index 0.4 No risk (0) 2 (1.8) 2 (2.4) 0 (0.0) Low risk (1-2) 43 (38.1) 30 (35.7) 13 (44.8) Moderate risk (3-4) 41 (36.3) 29 (34.5) 12 (41.4) High risk (5) 27 (23.9) 23 (27.4) 4 (13.8) Body Mass Index (BMI) (kg/m 2 ) 0.003 <20 (underweight) 23 (20.4) 11 (13.1) 12 (41.4) 20-24.9 (normal weight) 46 (40.7) 34 (40.5) 12 (41.4) 25-29.9 (overweight) 34 (30.1) 29 (34.5) 5 (17.2) ≥30 (obese) 10 (8.8) 10 (11.9) 0 (0.0) BSA 3.62 (±0.92) 3.71 (±0.93) 3.33 (±0.85) 0.05 C3 CSA 37.97 (±8.53) 39.19 (±8.23) 34.25 (±8.44) 0.007 L3 SMI 45.43 (±8.08) 46.83 (±7.66) 41.18 (±7.95) 0.001 Tumor type 0.5 Primary 99 (87.6) 72 (85.7) 27 (93.1) Recurrent 9 (8.0) 8 (9.5) 1 (3.4) Second primary 5 (4.4) 4 (4.8) 1 (3.4) Localization 0.9 Oral cavity 8 (7.1) 5 (6.0) 3 (10.3) Oropharynx 73 (64.6) 55 (65.5) 18 (62.1) Nasofarynx 3 (2.7) 2 (2.4) 1 (3.4) Hypopharynx 18 (15.9) 2 (2.4) 5 (17.2) Larynx 8 (7.1) 7 (8.3) 1 (3.4) Lymph node 3 (2.7) 2 (2.4) 1 (3.4) Human Papillomavirus Status 0.1 Negative 70 (61.9) 51 (60.7) 19 (65.5) Positive 16 (14.2) 15 (17.9) 1 (3.4) Not recorded 27 (23.9) 18 (21.4) 9 (31.0) 4